Introduction: The HEQ (Health Economics Questionnaire) is a comprehensive, self-reported health economics questionnaire measuring health and social care resource use, medication, absenteeism and presenteeism at work, other productivity impacts as well as socio-demographic background information. It was developed based on several years of international experience with within-trial (mental) health economic evaluations and implemented first in the multi-country European PreDicT study in 2016. Further language versions are also available in Dutch, French, German and Spanish.
To allow for resource-use measurement in times of pandemics, the questionnaire has been updated and complemented with a COVID-19 resource-use measurement module (Module 7) to capture further information about COVID-19 infections, self-isolation and related changes in health services use and employment status in 2020. The HEQ COVID-19 now both reflects the changed service provision landscape and having direct information on any COVID-19 related service use. The HEQ Covid-19 has been implemented for example in the UK-based PAX-BD study and the PAX-D study. Currently it is available in two languages: English and German.
Access: The use of the HEQ is free for non-commercial purposes and is conditional upon correct citation in any resulting work/publication. Samples of the baseline and follow-up English language questionnaires can be viewed here: https://doi.org/10.5281/zenodo.4559790
The use of the HEQ COVID-19 is free for non-commercial purposes and is conditional upon correct citation in any resulting work/publication. Samples of the baseline and follow-up English language questionnaires can be viewed here: https://doi.org/10.5281/zenodo.4559752
- Simon, J & Mayer, S (2016) HEQ (Health Economics Questionnaire), Version 08-09-2016, Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria. https://doi.org/10.5281/zenodo.4559790
- Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. (2017) The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: Study Protocol for a Randomised Controlled Trial. Trials. DOI: 10.1186/s13063-017-2247-2
- Simon, J & Mayer, S (2021): HEQ COVID-19, Version 24-02-2021, Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna. https://doi.org/10.5281/zenodo.4559752
- Azim L, Hindmarch P, Browne G, Chadwick T, Clare E, Courtney P, et al. Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). BMC Psychiatry. 2021 Jul 5;21:334. DOI: 10.1186/s12888-021-03322-y
Contact: For further information or commercial users, please send an email to email@example.com
Authors and copyright:
HEQ: © Judit Simon/Susanne Mayer, Medical University of Vienna, 2016
HEQ COVID-19: © Judit Simon/Susanne Mayer, Medical University of Vienna, 2020